GO:0005515 protein binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005515 protein binding is a molecular function defined as binding to a protein, with synonyms glycoprotein binding and protein amino acid binding.
• Protein binding underlies nearly every cellular process, from transcription factor specificity to drug pharmacokinetics and disease mechanisms.
• Binding interactions can be quantified by equilibrium dialysis, ultrafiltration, and protein-binding microarrays, but nonlinear binding complicates interpretation.
• Artificial intelligence and protein embeddings now predict binding residues and protein-protein interfaces with high accuracy.
• Altered protein binding is clinically significant in tuberculosis therapy, cancer, and neurodegeneration, affecting drug efficacy and toxicity.
• CRISPR knockout, point mutation, knock-in, and overexpression models enable causal testing of protein-binding interfaces in disease.
Description
Protein binding (GO:0005515) is a molecular function describing the selective interaction of a protein with another protein or glycoprotein. This term captures the physical association that governs enzyme-substrate recognition, signal transduction, and the assembly of macromolecular complexes. In pharmacology, protein binding determines the free fraction of a drug and thus its distribution, metabolism, and excretion, making it a central parameter in DMPK studies. Clinically, changes in protein binding can alter therapeutic index and toxicity, as seen with antituberculosis drugs and other agents. For researchers, GO:0005515 provides a unifying annotation for any gene product that binds a protein partner, enabling functional enrichment and network analysis across genomes. Understanding the structural and energetic basis of protein binding is therefore essential for drug discovery, systems biology, and precision medicine.
protein binding At A Glance
| GO ID | GO:0005515 |
|---|---|
| GO term | protein binding |
| Ontology | molecular_function |
| Synonym | glycoprotein binding; protein amino acid binding |
| Major function | Binding to a protein |
| Definition source | QuickGO |
| Related processes | Signal transduction, transcription regulation, drug disposition |
| Experimental detection | Protein-binding microarrays, equilibrium dialysis, AI prediction |
What Is GO:0005515?
GO:0005515 protein binding is defined as binding to a protein. It is a molecular function term in the Gene Ontology, with synonyms glycoprotein binding and protein amino acid binding. This term is used to annotate gene products that physically interact with one or more protein molecules, including transient and stable complexes, and it does not specify the identity of the binding partner or the biological outcome.
Why Is protein binding Important in Cell Biology?
Protein binding is fundamental to almost all biological processes because it mediates the assembly of complexes, the regulation of enzyme activity, and the recognition of substrates and ligands. In pharmacology, the extent of drug-protein binding directly influences free drug concentration and thus therapeutic efficacy and toxicity. In genomics, protein-binding microarrays have been used to dissect transcription factor specificity across homologs, isoforms, and complexes, revealing how subtle sequence changes alter DNA binding. Clinically, altered protein binding of antituberculosis drugs can lead to suboptimal exposure and treatment failure. Therefore, GO:0005515 is a critical annotation for interpreting gene function, disease mechanisms, and drug action.
• Protein binding governs enzyme-substrate recognition and metabolic pathways.
• It determines drug pharmacokinetics and pharmacodynamics through plasma protein binding.
• Transcription factor specificity and combinatorial regulation depend on protein-DNA and protein-protein binding.
• Protein-protein binding interfaces are key targets for therapeutic design and AI prediction.
• Altered binding of antituberculosis drugs affects clinical outcomes and resistance.
• Protein binding in disordered regions regulates signaling and phase separation.
• Glycoprotein binding is relevant to viral entry and immune recognition.
• Protein binding assays are essential for DMPK and ADME studies in drug development.
• Nonlinear protein binding can complicate dose-response predictions.
• Clinical significance of protein binding extends to anesthesia, oncology, and infectious disease.
Molecular Mechanism of protein binding
Binding site recognition and specificity
In simple terms: Proteins find their partners by matching complementary shapes and chemical groups.
Protein binding begins with the recognition of a binding interface, often a pocket or a flat surface, that is complementary in shape, charge, and hydrophobicity to the partner protein. Protein-binding microarrays have revealed that transcription factors can discriminate among closely related sequences, and that homologs, isoforms, and complexes exhibit distinct binding specificities. AI methods now encode the space of protein-protein binding interfaces, enabling prediction of binding residues even in disordered regions.
Thermodynamics and kinetics of association
In simple terms: Binding strength and speed depend on how well the partners fit and how long they stay together.
The affinity of protein binding is governed by the equilibrium dissociation constant (Kd), which reflects the ratio of association and dissociation rates. Nonlinear protein binding, where the free fraction changes with concentration, is common for drugs and can lead to non-proportional increases in free drug at high concentrations. These principles are critical for interpreting drug-protein binding in ADME studies.
Conformational changes and induced fit
In simple terms: Proteins can change shape when they bind, like a hand fitting into a glove.
Many protein interactions involve conformational changes that optimize the interface, a process known as induced fit. This is particularly relevant for disordered regions, where binding often involves coupled folding and binding. Protein embeddings have been used to predict binding residues in disordered regions, highlighting the importance of flexibility in recognition.
Regulation by post-translational modifications and cofactors
In simple terms: Chemical tags or helper molecules can switch binding on or off.
Post-translational modifications such as phosphorylation, acetylation, and glycosylation can modulate protein binding by altering charge or steric hindrance. Glycoprotein binding is explicitly included in the synonymy of GO:0005515, reflecting the importance of carbohydrate moieties in recognition. Cofactors and ions can also stabilize interfaces or induce conformational states that favor binding.
Multivalent and allosteric interactions
In simple terms: Proteins can bind multiple partners at once, and binding at one site can change another.
Multivalent binding, where a protein engages several partners simultaneously, increases avidity and specificity. Allosteric coupling allows binding at one site to affect affinity at a distant site, a mechanism widely used in signaling and drug action. Protein-binding microarrays have been used to study complexes and higher-order assemblies, revealing how multivalency shapes transcription factor function.
Key Genes Involved in GO:0005515 protein binding
The following genes and proteins are representative examples of products annotated with protein binding (GO:0005515) and are widely studied in pharmacology, transcription, and disease.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TP53 | Binds DNA and proteins to regulate cell cycle and apoptosis | Cancer biology and drug response |
| EGFR | Binds growth factors and adaptor proteins | Targeted therapy in lung cancer |
| HSP90AA1 | Chaperone that binds client proteins | Protein folding and cancer |
| CALM1 | Calcium-binding protein that binds target enzymes | Signal transduction |
| ACTB | Cytoskeletal protein that binds many partners | Cell motility and structure |
| TUBB | Tubulin that binds microtubule-associated proteins | Cytoskeleton and mitosis |
| GAPDH | Glycolytic enzyme with diverse protein interactions | Metabolism and apoptosis |
| STAT3 | Transcription factor that binds DNA and proteins | Inflammation and cancer |
| NFKB1 | Transcription factor subunit with multiple binding partners | Immune signaling |
| MAPK1 | Kinase that binds substrates and scaffolds | Proliferation signaling |
| AKT1 | Kinase with pleckstrin homology domain binding lipids and proteins | Survival signaling |
| MTOR | Kinase that binds raptor and other proteins | Growth and metabolism |
| CDK2 | Cyclin-dependent kinase that binds cyclins | Cell cycle regulation |
| BCL2 | Binds pro-apoptotic proteins | Apoptosis and cancer |
| VEGFA | Binds receptors and co-receptors | Angiogenesis |
| IL6 | Cytokine that binds receptor complexes | Inflammation |
| TNF | Binds TNF receptors | Immune response |
How Is protein binding Regulated?
Protein binding is regulated at multiple levels, including expression levels of binding partners, post-translational modifications, and the presence of competing ligands. In drug discovery, plasma protein binding is a key determinant of free drug concentration and can be saturable, leading to nonlinear pharmacokinetics. Clinical significance of protein binding is well recognized, as changes in binding can alter drug effects. For antituberculosis drugs, protein binding investigations help optimize dosing and predict efficacy. At the molecular level, AI models are being developed to predict how mutations affect binding interfaces, which can inform regulation studies.
protein binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TP53 | Cancer (Li-Fraumeni, many sporadic tumors) | Knockout and point-mutation cell lines |
| EGFR | Non-small cell lung cancer | Knock-in of activating mutations |
| STAT3 | Inflammation and cancer | Overexpression and knockout models |
| BCL2 | Lymphoma and apoptosis resistance | Knockout and knock-in of BH3 mutations |
| MTOR | Cancer and metabolic disorders | Point mutation of kinase domain |
Protein binding in infectious disease and drug therapy
Protein binding of antituberculosis drugs such as rifampicin and isoniazid influences their free concentrations and thus bactericidal activity. Fage et al. investigated protein binding of first-line and second-line antituberculosis drugs, highlighting the need to account for binding in pharmacokinetic/pharmacodynamic modeling. Similarly, the clinical significance of protein binding has been recognized for decades, affecting drug distribution and clearance.
Protein binding in cancer and signal transduction
Many oncoproteins function through protein-protein interactions. For example, transcription factors such as STAT3 and NFKB1 bind DNA and cofactors to drive oncogenic gene expression. Protein-binding microarrays have been used to study transcription factor specificity, revealing how isoforms and complexes contribute to cancer gene regulation. AI prediction of binding interfaces is now aiding the design of inhibitors targeting these interactions.
Protein binding in neurodegeneration and disordered proteins
Disordered regions often mediate protein binding in signaling and neurodegeneration. Jahn et al. developed protein embeddings to predict binding residues in disordered regions, which is relevant to understanding pathological interactions in neurodegenerative diseases. Such interactions are potential therapeutic targets.
From protein binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a binding partner affect complex formation? | CRISPR knockout |
| Does a specific point mutation disrupt binding? | Point mutation knock-in |
| Can a tagged protein rescue binding in vivo? | Tagged knock-in |
| Does overexpression of a binding protein alter signaling? | Overexpression |
| Which binding interfaces are essential for drug response? | CRISPR library screening |
| How do mutations affect protein-protein interactions? | Bioinformatics and AI prediction |
How to Study the protein binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Protein-binding microarray | Relative binding affinity for DNA/protein partners | Transcription factor specificity |
| Equilibrium dialysis | Free vs bound drug fraction | Plasma protein binding |
| Ultrafiltration | Free drug concentration | DMPK studies |
| AI embedding prediction | Binding residues and interfaces | Disordered region binding |
| CRISPR knockout screen | Gene requirement for binding phenotype | Functional genomics |
| Co-immunoprecipitation | Physical interaction between proteins | Complex assembly |
| Surface plasmon resonance | Kinetics of binding (kon, koff) | Affinity characterization |
Protein-binding microarrays
Protein-binding microarrays (PBMs) are high-throughput methods to study protein-DNA and protein-protein interactions. They have been used to dissect transcription factor specificity across homologs, isoforms, and complexes, providing quantitative binding profiles.
Equilibrium dialysis and ultrafiltration
These classic methods measure the free fraction of a drug or ligand in the presence of proteins. They are essential for determining plasma protein binding and are widely used in DMPK studies.
AI and protein embeddings
Machine learning models using protein embeddings can predict binding residues in disordered regions and encode protein-protein binding interfaces. These computational approaches complement experimental methods and enable high-throughput annotation.
CRISPR screening and functional genomics
CRISPR knockout and activation screens can identify genes whose products are required for specific protein-binding events or drug responses. Such screens link binding function to cellular phenotypes.
How CRISPR Can Be Used to Study GO:0005515 protein binding
Knockout
CRISPR knockout of a gene encoding a protein-binding partner can abolish complex formation and reveal its functional importance. For example, knocking out STAT3 in cancer cell lines can reduce binding to coactivators and alter gene expression.
Point Mutation
Point mutations can be introduced to disrupt specific binding interfaces while preserving overall protein structure. This is useful for testing the contribution of individual residues to binding affinity and downstream signaling.
Knock-in
Knock-in of tagged or mutant versions of a protein allows tracking of binding dynamics and rescue experiments. Tagged knock-in models are valuable for imaging and proteomics.
Overexpression
Overexpression of a binding protein can titrate out partners or enhance complex formation, providing insights into dose-dependent effects. This approach is often used to study oncogenic transcription factors.
How EDITGENE Supports protein binding Research
Researchers studying protein binding-related genes often need to determine whether a candidate gene is causally involved in a specific interaction or disease phenotype. EDITGENE provides a comprehensive suite of CRISPR services to enable such causal studies.
Contact EDITGENE today to design your custom CRISPR model for protein binding research.
Frequently Asked Questions About protein binding
What is GO:0005515 protein binding?
GO:0005515 is a Gene Ontology molecular function term defined as binding to a protein, with synonyms glycoprotein binding and protein amino acid binding.
What genes are involved in protein binding?
Many genes encode proteins that bind other proteins, including TP53, EGFR, STAT3, and MTOR, as annotated in the Gene Ontology.
How is protein binding measured?
Common methods include protein-binding microarrays, equilibrium dialysis, ultrafiltration, and surface plasmon resonance.
Why is protein binding important in drug development?
Protein binding affects free drug concentration, distribution, and clearance, making it a key parameter in DMPK and ADME studies.
What is the clinical significance of protein binding?
Changes in protein binding can alter drug efficacy and toxicity, as seen with antituberculosis drugs and other agents.
Can AI predict protein binding?
Yes, protein embeddings and machine learning models can predict binding residues and interfaces, including in disordered regions.
What is nonlinear protein binding?
Nonlinear protein binding occurs when the free fraction changes with drug concentration, often due to saturable binding sites.
How do CRISPR models help study protein binding?
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of binding interfaces and their downstream effects.
What is glycoprotein binding?
Glycoprotein binding is a synonym for protein binding, referring to binding to glycoproteins, which are proteins with carbohydrate modifications.
Which diseases involve altered protein binding?
Altered protein binding is implicated in infectious diseases, cancer, and neurodegeneration, among others.
Conclusion
GO:0005515 protein binding is a fundamental molecular function that underpins drug action, signal transduction, and disease mechanisms. Its annotation enables functional genomics and drug discovery, while experimental and computational methods continue to advance our understanding of binding specificity and regulation. EDITGENE provides the CRISPR tools needed to causally test protein-binding hypotheses in relevant cell models.
References
- 1. Deitchman AN et al.. 2018. Nonlinear Protein Binding: Not What You Think.. J Pharm Sci 107(7):1754-1760 PMID: 29626534
- 2. Xie V. 2022. Understanding drug-protein binding and ADME studies for DMPK.. Bioanalysis 14(13):919-921 PMID: 35703337
- 3. Buchanan N. 1978. Protein binding of drugs--the clinical significance.. S Afr Med J 53(22):883-6 PMID: 356286
- 4. Jahn LR et al.. 2024. Protein embeddings predict binding residues in disordered regions.. Sci Rep 14(1):13566 PMID: 38866950
- 5. Weber WW. 1972. Protein binding.. Adv Biol Skin 12:61-3 PMID: 4579207
- 6. Andrilenas KK et al.. 2015. Using protein-binding microarrays to study transcription factor specificity: homologs, isoforms and complexes.. Brief Funct Genomics 14(1):17-29 PMID: 25431149
- 7. Fage D et al.. 2023. Protein binding investigation of first-line and second-line antituberculosis drugs.. Int J Antimicrob Agents 62(6):106999 PMID: 37838149
- 8. Su Z et al.. 2024. Encoding the space of protein-protein binding interfaces by artificial intelligence.. Comput Biol Chem 110:108080 PMID: 38643609
